• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Primary amines

Recent Advances in the Application of (1R)-1-cyclopropylethanamine (CAS: 6240-96-6) in Chemical Biology and Pharmaceutical Research

The compound (1R)-1-cyclopropylethanamine (CAS: 6240-96-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This chiral amine, characterized by its cyclopropyl group, serves as a versatile building block in the synthesis of various bioactive molecules. Recent studies have explored its role in the development of novel drug candidates, particularly in the areas of central nervous system (CNS) disorders and infectious diseases.

One of the most notable advancements involves the incorporation of (1R)-1-cyclopropylethanamine into the design of selective serotonin reuptake inhibitors (SSRIs) and other neuromodulators. Researchers have demonstrated that the cyclopropyl moiety enhances the binding affinity of these compounds to their target receptors, thereby improving their efficacy and reducing off-target effects. For instance, a 2023 study published in the Journal of Medicinal Chemistry highlighted the use of this compound in the synthesis of a new class of antidepressants with improved pharmacokinetic profiles.

In addition to its applications in CNS drug development, (1R)-1-cyclopropylethanamine has also been investigated as a key intermediate in the synthesis of antiviral agents. Recent research has shown that derivatives of this compound exhibit potent activity against RNA viruses, including SARS-CoV-2. A study conducted by a team at the University of California, San Francisco, revealed that these derivatives interfere with viral replication by inhibiting the viral RNA-dependent RNA polymerase (RdRp), offering a promising avenue for the development of broad-spectrum antiviral therapies.

Furthermore, the compound's role in asymmetric synthesis has been a focal point of recent investigations. Its chiral nature makes it an excellent candidate for the production of enantiomerically pure pharmaceuticals, which are increasingly demanded in the industry. Advances in catalytic methods have enabled the efficient and scalable synthesis of (1R)-1-cyclopropylethanamine, as reported in a 2022 article in Organic Letters. These developments are expected to facilitate its broader adoption in pharmaceutical manufacturing.

Despite these promising findings, challenges remain in the optimization of (1R)-1-cyclopropylethanamine-based therapeutics. Issues such as metabolic stability and bioavailability need to be addressed through further structural modifications and preclinical studies. Nonetheless, the compound's versatility and potential for diverse applications underscore its importance in contemporary drug discovery efforts. Future research is likely to focus on expanding its utility in targeted therapies and personalized medicine, leveraging its unique chemical properties to address unmet medical needs.

• 61888-94-6(Bicyclo[5.1.0]octan-8-amine)
• 1342230-69-6(2-(2-methylpropyl)cyclopropan-1-amine)
• 2350910-11-9((1S,2R)-2-Ethyl-cyclopropylamine)
• 777010-06-7(Bicyclo[5.1.0]octan-2-amine,(1R,2S,7S)-rel-)
• 2324750-29-8((1S,2S)-2-Ethyl-cyclopropylamine)
• 1369571-54-9(rac-(1R,2S)-2-cyclopropylcyclopropan-1-amine)
• 1202174-17-1(2-Propylcyclopropan-1-amine)
• 1640973-33-6(Cyclopropanamine, 2-butyl-, (1R,2S)-rel-)
• 1820580-67-3(Cyclopropanamine, 2-(2-methylpropyl)-, (1R,2R)-)
• 1820569-09-2((1R,2R)-2-Ethyl-cyclopropylamine)